Better Buy: Ramsay Health Care Limited vs Healthscope Ltd

The private hospital sector is exposed to two very attractive tailwinds:

  • A globally ageing population that will result in an increase in the number of patient hospitalisations
  • Support from governments that are finding it increasingly more difficult to fund the ballooning costs of healthcare through the public system

Ramsay Health Care Limited (ASX: RHC) and Healthscope Ltd (ASX: HSO) are Australia’s two largest private hospital operators and both have significantly outperformed the broader market over the past couple of years.

Investors would probably be more familiar with Ramsay because of its impeccable and long track record but this doesn’t mean Healthscope should be overlooked.

To get a better overview of both companies, here is a quick comparison of some of their key metrics:


Ramsay has a market capitalisation of $14.4 billion and operates 221 hospitals with 25,000 beds. It generates 52% of its revenues in Australia, 39% in France and the remaining 9% in Asia and the UK.

Healthscope has a market capitalisation of $4.8 billion, operates 46 hospitals, 53 medical centres and also has a New Zealand pathology division. Around 83% of the company’s earnings are generated from the Australian hospitals division.

Revenue, Earnings and Dividend History

In its latest half year report, Ramsay generated revenues of $4.2 billion, up 24.9% over the previous period. Core earnings per share increased by 16.9% and this was consistent with the company’s impressive long term growth rate of 16.8%, as highlighted below.

Source: Company Presentation

Source: Company Presentation

Ramsay was also able to increase its interim dividend by 16% to 47 cents per share (fully franked), in line with its long term growth rate of 16.6%.

Healthscope has only been listed in its current structure since 2014, so it is more difficult to get an accurate picture of its long term performance.

As the graph below shows, Healthscope has only recorded three halves of earnings with the most recent result showing revenue growth of 5.5% to $1.15 billion and earnings per share growth of 14.6%.

Source: Healthscope Interim Results Presentation

Source: Healthscope Interim Results Presentation

The company increased its dividend by 6% to 3.5 cents per share, although this was unfranked.

Operating Margins

Comparing operating margins from their most recent results, Healthscope comes out on top with an EBIT margin of 13.9% compared to Ramsay’s margin of 10.2%.

Balance Sheet

Both companies carry a significant level of debt which is needed to fund the high levels of capital expenditure required to build and maintain hospitals.

This balance sheet risk is offset somewhat by the fact that both companies generate high levels of operational cash flows which provides a nice cushion to manage those debt levels.

In the case of Ramsay, it has a net debt of around $3.2 billion and a net-debt to equity ratio of around 166%.

Healthscope has a net debt of around $1.1 billion and a net-debt to equity ratio of around 48%.

Development Pipeline

Both hospital operators have healthy project pipelines that should be converted into future earnings growth.

Ramsay will look to add an additional 310 beds and 12 operating theatres over the next 12 months, while Healthscope has plans to add 163 beds and 9 operating theatres by the end of FY16.


Ramsay recently upgrade its full year profit guidance and expects to deliver core EPS growth of 15%-17% for FY16.

Healthscope has not provided any firm earnings guidance for the remainder of FY16, but has noted that it expects ongoing improvements throughout the year and for accelerated growth in FY17 and beyond.


Ramsay is currently trading on a price-to-earnings (P/E) ratio of around 30 and a dividend yield of 1.6%.

Healthscope is currently trading on a P/E ratio of 24 and a dividend yield (unfranked) of 2.6%.

Foolish takeaway

Both companies have exciting futures ahead of them but this looks to be suitably priced in the current valuation of both companies.

While Ramsay remains my preferred company in the sector thanks to its exposure offshore and long term record, I don’t think investors should overlook Healthscope especially if its shares become cheaper from here.

Looking for more high quality companies like Ramsay Health Care and Healthscope?

Discover the 'new breed' of blue chips that could take your portfolio higher in 2016

Forget BHP and Woolworths. These 3 "new breed" top blue chips for 2016 pay fully franked dividends and offer the very real prospect of significant capital appreciation. Click here to learn more.

The report is free! No credit card required.

Motley Fool contributor Christopher Georges has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.